The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review
Patients with osteoporosis and impaired renal function are at risk